SEL-212

· Swedish Orphan Biovitrum AB (Sobi)

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for SEL-212, covering 2017-01-30 to 2025-12-03. Get the full timeline:

Most recent: Clinical Trial Update: A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II [Phase 3]